Skip to content

Charles River Laboratories CRL Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation

Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation at other companies

Plexus logo
PlexusPLXS
-$57.34M-93.6%
Revvity logo
RevvityRVTY
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST

Other financials

Income statement

See full
Revenue$995.8M+1.2%
Gross profit$349.0M-3.5%
Operating income$119.9M+60.6%
Net income-$14.8M-158%
EPS (diluted)-$0.30-160%

Balance sheet

See full
Cash & equivalents$198.2M-14.5%
Total debt$3.1B+1.9%
Total equity$2.9B-7.9%
Total assets$7.7B+2.0%

Cash flow

See full
Operating cash flow$41.1M-76.1%
CapEx$55.9M-5.8%
Free cash flow-$14.8M-113%

Valuation

See full
Market cap$8.91B+10.3%
Enterprise value$11.79B+8.5%
P/S2.2×+0.2×

Profitability

See full
Gross margin84.7%
Operating margin13%-2.4pp
Net margin-4.6%
FCF margin9.7%-4.3pp

Returns & leverage

See full
Return on equity-6%
Debt / equity+0.1×
Current ratio1.4×-0.1×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Charles River Laboratories's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Charles River Laboratories's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation?
Charles River Laboratories (CRL) reported cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation of -$17.8M in Q1 2026.
How has Charles River Laboratories's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation changed year-over-year?
Charles River Laboratories's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation decreased by 168.0% year-over-year, from $26.16M to -$17.8M.
What does cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation mean?
The total increase or decrease in the company's cash and restricted cash balances during the period.
How do you interpret cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation?
A positive value indicates net cash generation, while a negative value indicates a net reduction in the company's liquid assets.
How does cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation compare across companies?
A fundamental metric for assessing short-term financial health across all industries.